Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick L Locke

Showing results (31-40 of 234) with videos related to

Pageof 24
Sort By:
Cancers|June 13, 2025
Radiomic Features Prognosticate Treatment Response in CAR-T Cell TherapyYoganand Balagurunathan, Jung W Choi, Zachary Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2025
Reply to: Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell Lymphoma: The Role of KIR MatchingFrederick L Locke, John B Le Gall, Paul W Fisher, et al.
Journal for Immunotherapy of Cancer|May 21, 2015
Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myelomaFrederick L Locke, Meghan Menges, Anandharaman Veerapathran, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 16, 2013
Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy inductionFrederick L Locke, Yuan-yuan Zha, Yan Zheng, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|June 19, 2026
Correction: Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) TherapyBrandon Blue, Paige Lake, Joseph Pidala, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|May 30, 2026
Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) TherapyBrandon Blue, Paige Lake, Joseph Pidala, et al.
JACC. Case Reports|March 2, 2023
Case of Myocarditis After Chimeric Antigen Receptor T Cells With Intracardiac LymphomaDae Hyun Lee, Michael Jain, Aleksandr Lazaryan, et al.
Journal of the American College of Cardiology|May 16, 2020
Reply: Cardiac Events Associated With Chimeric Antigen Receptor T Cells (CAR-T): A VigiBase PerspectiveRaza M Alvi, Michael G Fradley, Matthew J Frigault, et al.
Transplantation and Cellular Therapy|September 30, 2022
Response to: Perceived Cognitive Changes Following Chimeric Antigen Receptor T Cell Therapy in Lymphoma: Perceptual Anticipation?Anna Barata, Aasha I Hoogland, Brent J Small, et al.
Cancer Control : Journal of the Moffitt Cancer Center|September 10, 2015
Recurrent Systemic Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma Presenting as a Breast Implant-Associated LesionAmanda Zimmerman, Frederick L Locke, Josephine Emole, et al.
Pageof 24

Showing results (31-40 of 234) with videos related to

Sort By:
Pageof 24
Cancers|June 13, 2025
Radiomic Features Prognosticate Treatment Response in CAR-T Cell TherapyYoganand Balagurunathan, Jung W Choi, Zachary Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2025
Reply to: Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell Lymphoma: The Role of KIR MatchingFrederick L Locke, John B Le Gall, Paul W Fisher, et al.
Journal for Immunotherapy of Cancer|May 21, 2015
Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myelomaFrederick L Locke, Meghan Menges, Anandharaman Veerapathran, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 16, 2013
Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy inductionFrederick L Locke, Yuan-yuan Zha, Yan Zheng, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|June 19, 2026
Correction: Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) TherapyBrandon Blue, Paige Lake, Joseph Pidala, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|May 30, 2026
Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) TherapyBrandon Blue, Paige Lake, Joseph Pidala, et al.
JACC. Case Reports|March 2, 2023
Case of Myocarditis After Chimeric Antigen Receptor T Cells With Intracardiac LymphomaDae Hyun Lee, Michael Jain, Aleksandr Lazaryan, et al.
Journal of the American College of Cardiology|May 16, 2020
Reply: Cardiac Events Associated With Chimeric Antigen Receptor T Cells (CAR-T): A VigiBase PerspectiveRaza M Alvi, Michael G Fradley, Matthew J Frigault, et al.
Transplantation and Cellular Therapy|September 30, 2022
Response to: Perceived Cognitive Changes Following Chimeric Antigen Receptor T Cell Therapy in Lymphoma: Perceptual Anticipation?Anna Barata, Aasha I Hoogland, Brent J Small, et al.
Cancer Control : Journal of the Moffitt Cancer Center|September 10, 2015
Recurrent Systemic Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma Presenting as a Breast Implant-Associated LesionAmanda Zimmerman, Frederick L Locke, Josephine Emole, et al.
Pageof 24